Source comparison
PT-141 20s Age Specific Protocol: Comparison to Standard Dosing
Standard Adult Protocol (FDA reference) 1.0–1.75mg SC +0.5mg increments 18–25% nausea rate in trials Designed for median age 42. Lower baseline MC4R density Appropriate for users 35+ but overshoots therapeutic window in younger cohorts PT-141 20s Age Specific
This comparison does not assign a generated winner or score.
- Standard Adult Protocol (FDA reference)
- 1.0–1.75mg SC
- +0.5mg increments
- 18–25% nausea rate in trials
- Designed for median age 42. Lower baseline MC4R density
- Appropriate for users 35+ but overshoots therapeutic window in younger cohorts
- PT-141 20s Age Specific Protocol
- 0.5–0.75mg SC
- +0.25mg increments
- 1.0–1.25mg
- Estimated 8–12% nausea rate
- Calibrated for peak MC4R expression ages 20–29
- Conservative titration leverages higher receptor availability. Achieves effect at lower plasma levels
- High-Dose Escalation (user-initiated, off-label)
- 1.75mg+ SC
- Rapid escalation beyond 2mg
- 2.0–2.5mg
- >40% adverse event rate in younger users
- Ignores receptor density variability. Oversaturates MC4R binding sites
- Overshooting optimal dose causes disproportionate side effects without added benefit in high-density receptor populations